在阿尔茨海默氏病中,PACAP-Sirtuin3通过自缓解认知障碍
Qing Wang1,2,3, Yue Wang1,2,3, Shiping Li4,5,6
1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119, South 4Th Ring West Road, Fengtai District, Beijing, 100070, China.
Alzheimer's research & therapy
|October 27, 2023
概括
垂体腺酸环酶激活聚 (PACAP) 增强了自,以逆转阿尔茨海默病 (AD) 的认知缺陷. 这项研究突显了PACAP在阿尔茨海默病中的治疗潜力,通过通过sirtuin3调节自.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 自在像阿尔茨海默氏症 (AD) 这样的神经退行性疾病中起着至关重要的作用.
- 甲状腺腺酸环酶激活多 (PACAP) 与AD病变发生过程中的自之间的关系仍然未被探索.
- 这项研究使用多种模型研究了PACAP和AD的自之间的相互作用.
研究的目的:
- 调查PACAP在调节阿尔茨海默氏病中自的作用.
- 探索PACAP在逆转AD引起的认知障碍方面的治疗潜力.
- 阐明PACAP对阿尔茨海默氏症自的作用背后的分子机制.
主要方法:
- 使用了体外和体内AD模型,包括在AD小鼠中注射鼻腔PACAP.
- 采用行为分析,实时定量PCR,RNA测序,免疫光和西部涂抹来评估PACAP的影响.
- 使用ELISA分析了人血清中的外体,以检查自途径和生物标志物协会.
主要成果:
- 在AD模型中,PACAP的使用增强了自和减弱了认知衰退.
- RNA测序确定PI3K-AKT,mTOR和AMPK通路可能与AD进展有关.
- 鉴定出Sirtuin3是关键的调解剂,其降低降低了PACAP对自的修复作用,导致蛋白质聚合.
结论:
- 通过增强自,PACAP可以扭转与AD相关的认知障碍,而sirtuin3则起到了关键的调解作用.
- 在人类血清中自生物标志物MAP1LC3和PACAP水平之间观察到正相关性.
- 鼻内PACAP和sirtuin3激动剂显示出作为阿尔茨海默病潜在治疗策略的前景.
相关概念视频
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
131
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
131
01:27Autophagy
4.3K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.3K